Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis.

Blood - 1 Oct 2007

Shachaf Catherine M, Perez Omar D, Youssef Sawsan, Fan Alice C, Elchuri Sailaja, Goldstein Matthew J, Shirer Amy E, Sharpe Orr, Chen Joy, Mitchell Dennis J, Chang Maria, Nolan Garry P, Steinman Lawrence, Felsher Dean W

Abstract excerpt

Statins are a class of drugs that inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMGcoA) reductase, a critical enzyme in the mevalonate pathway. Several reports document that statins may prevent different human cancers. However, whether or not statins can prevent cancer is controversial due to discordant results. One possible explanation for these conflicting conclusions is that only some tumors or specific...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Atorvastatin
Share to Glycine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heptanoic Acids

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Hydroxymethylglutaryl CoA Reductases

Share to Lymphoma

Share to Precancerous Conditions

Share to Pyrroles

Source

Open in PubMed Open full text

Identifiers

PMID: 17622571
DOI: 10.1182/blood-2006-09-048033
PMCID: PMC1988916

Genes

MYC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis.PMID 17622571Read ↗

MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase.Semantic proximity Read ↗

Genome-wide RNAi analysis reveals that simultaneous inhibition of specific mevalonate pathway genes potentiates tumor cell deathSemantic proximity Read ↗

Mevalonate Pathway and Human Cancers.Semantic proximity Read ↗

The role of statins as therapeutic agents in cancerSemantic proximity Read ↗

Statins are potential anticancerous agents (Review)Semantic proximity Read ↗

Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myelomaSemantic proximity Read ↗

Mevastatin can cause G1 arrest and induce apoptosis in pulmonary artery smooth muscle cells through a p27Kip1-independent pathway.Semantic proximity Read ↗

HMG-CoA reductase promotes protein prenylation and therefore is indispensible for T-cell survival.Semantic proximity Read ↗

Targeting the mevalonate pathway is a novel therapeutic approach to inhibit oncogenic FoxM1 transcription factor in human hepatocellular carcinomaSemantic proximity Read ↗

Statin as anti-cancer therapy in autochthonous T-lymphomas expressing stabilized gain-of-function mutant p53 proteinsSemantic proximity Read ↗

Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression.Semantic proximity Read ↗

Lipophilic statins antagonistically alter the major epithelial‐to‐mesenchymal transition signaling pathways in breast cancer stem–like cells via inhibition of the mevalonate pathwaySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.